Showing results 1 to 1 of 1
| Title | Author(s) | Issue Date | |
|---|---|---|---|
380MO A phase II trial of atezolizumab, bevacizumab, pemetrexed and carboplatin combination for metastatic EGFR-mutated NSCLC after TKI failure Proceeding/Conference:Annals of Oncology | 2020 |